临床外科杂志 ›› 2024, Vol. 32 ›› Issue (2): 199-202.doi: 10.3969/j.issn.1005-6483.2024.02.020

• 论著 • 上一篇    下一篇

血清miR-141对结直肠癌的诊断价值及根治性切除术后水平的变化

  

  1. 723000   陕西省汉中市,三二〇一医院胃肠外科 
  • 收稿日期:2023-03-20 修回日期:2023-03-20 接受日期:2023-03-20 出版日期:2024-02-20 发布日期:2024-02-20

Diagnostic value of serum miR-141 in colorectal cancer and changes of serum miR-141 level after radical resection

  1. Department of Gastrointestinal Surgery,3201 Hospital,Shaanxi,Hanzhong 723000,China
  • Received:2023-03-20 Revised:2023-03-20 Accepted:2023-03-20 Online:2024-02-20 Published:2024-02-20

摘要: 目的  探讨血清miR-141对结直肠癌(CRC)的诊断价值及根治性切除术后水平的变化。方法  收集2019年4月~2021年3月我院75例CRC病人(CRC组)和20例因腹股沟疝而接受计划手术病人(非癌对照组)的手术组织和血清样本,进行miRNA微阵列分析。采用实时荧光定量PCR(qRT-PCR)检测术前和术后第3天时血清样本中miR-141的表达水平。结果 经miRNA微阵列分析,与非癌对照组比较,CRC组病人组织和血清样本中有12种miRNAs同时表达上调,其中miR-141上调最显著。经qRT-PCR法检测,CRC组病人术前血清miR-141相对表达量高于非癌对照组[2.50(1.06,3.12)vs.0.97(0.68,1.21),Z=-5.842,P<0.05]。经ROC曲线分析,术前血清miR-141用于诊断CRC的AUC值为0.927(95%CI:0.862~0.992),当血清miR-141≥1.418时,用于区分CRC组和非癌对照组人群时的准确性为90.53%。联合检测血清miR-141可将癌胚抗原、糖类抗原-199的临床诊断AUC值提高至0.944(95%CI:0.899~0.998)。对于CRC组病人,接受根治性切除者术后血清miR-141相对表达量显著低于术前[1.85(1.29,2.22) vs.2.55(2.07,3.18),Z=-5.416,P<0.001],对于未接受根治性切除术者,术后血清miR-141相对表达量略低于术前[2.28(1.72,2.74)vs.2.45(2.06,2.85)],但差异无统计学意义(Z=-1.917,P=0.055)。CRC病人术前血清miR-141表达水平与肿瘤UICC分期和组织学分级有关(P<0.05)。结论 血清miR-141反映了CRC病人的病理变化,有望成为无创诊断CRC的有希望的生物标记物。

关键词: 血清, miRNAs微阵列, 结直肠癌, 诊断

Abstract: Objective To investigate the potential value of miR-141 as a diagnostic blood biomarker expression level in patients with colorectal cancer(CRC) and its change after radical CRC resection.Methods 75 CRC patients admitted to Affiliated to Medical College of Xi’an Jiaotong University 3201 Hospital from April 2019 to March 2021 were included in the experimental group,and 20 patients who received planned surgery for inguinal hernia during the same period were used as non-cancer control group.Surgical tissue and serum samples of these patients were collected.Microarray analysis was performed for miRNAs with significant expression differences in CRC tissues and serum.Real-time quantitative PCR(qRT-PCR) was used to verify the expression level of miR-141 in serum samples of the patients before surgery and at the 3rd day after surgery,and the relationship between miR-141 and clinicopathological characteristics of CRC patients was analyzed.Results By miRNA microarray analysis, we confirmed that 12 miRNAs were up-regulated simultaneously in tissue and serum samples of CRC patients,among which miR-141 was the most significantly up-regulated.Meanwhile,the relative expression level of miR-141 in serum of CRC group was significantly higher than that of non-cancer control group after qRT-PCR verification[2.50(1.06,3.12)vs.0.97(0.68,1.21),Z=-5.842,P<0.05].According to ROC curve analysis, the AUC value of preoperative serum miR-141 for the diagnosis of CRC was 0.927(95%CI:0.862~0.992).When serum miR-141≥1.418, the accuracy of distinguishing between CRC and non-cancer control groups was 90.53%.Combined detection of serum miR-141 could increase the diagnostic AUC value of carcinoembryonic antigen and carbohydrate antigen 199 to 0.944(95%CI:0.899~0.998).For CRC patients, the relative expression level of serum miR-141 after radical resection was significantly lower than that before surgery[1.85(1.29,2.22) vs.2.55(2.07,3.18),Z=-5.416,P<0.001].For those who did not receive radical resection, the relative expression level of serum miR-141 after surgery was slightly lower than that before surgery[2.28(1.72,2.74)vs.2.45(2.06,2.85)],but the difference was not statistically significant(Z=-1.917,P=0.055).The expression level of Mir- 141 in serum of CRC patients was correlated with UICC stage and histological grade(P<0.05).Conclusion Serum miR-141 reflects the pathological changes of CRC patients and can be used as a biomarker for noninvasive diagnosis of CRC.

Key words: serum, miRNAs microarray, colorectal cancer, diagnosis

[1] 苏政军 黄珊珊 陈万进. 血清纤维胶凝蛋白3、胶原三股螺旋重复蛋白1对非小细胞肺癌的诊断价值及与临床病理特征的关系[J]. 临床外科杂志, 2024, 32(2): 164-167.
[2] 张庭 闫书山 于淇 段全红. 外泌体在结直肠癌侵袭转移作用的研究进展[J]. 临床外科杂志, 2024, 32(2): 214-215.
[3] 郑三侠 陈佳锦 董明明 李新明. 腹股沟直疝腹腔镜下经腹腹膜前疝修补术术中三种不同假疝囊处理方法的效果比较[J]. 临床外科杂志, 2024, 32(1): 79-82.
[4] 付锦程 付涛. 泛素特异性蛋白酶7功能和在结直肠癌中的研究进展[J]. 临床外科杂志, 2024, 32(1): 106-109.
[5] 刘峻峰 金方童 刘晓平. 同时性早期胃癌合并肺癌一例[J]. 临床外科杂志, 2024, 32(1): 111-112.
[6] 乔玥玥 刘淑桢 张坤. 直肠恶性肿瘤伴肝包虫病一例[J]. 临床外科杂志, 2023, 31(9): 842-843.
[7] 王梓义 左林丹 廖志敏 郑威 黄维江. 肺纯磨玻璃结节(直径≤3cm)的侵袭性预测[J]. 临床外科杂志, 2023, 31(9): 844-847.
[8] 罗兴红 杨柳 董琪 田爱霞 龙丹. 肝癌病人血清中长链非编码RNA BSN-AS2、hsa-miR-4782-3p表达水平及其临床诊断价值分析[J]. 临床外科杂志, 2023, 31(9): 852-855.
[9] 梁林虎 张峥嵘 李浩然 程正武 江厚象. 结直肠癌切除术病人嗜神经侵袭情况及其与预后的相关性研究[J]. 临床外科杂志, 2023, 31(8): 773-777.
[10] 吴海燕 邵泽生 崔恒锋. 结直肠癌病人白蛋白、碱性磷酸酶水平对腹腔镜根治术后淋巴结转移的预测[J]. 临床外科杂志, 2023, 31(7): 654-658.
[11] 李璐 孙桂东 邵万金. 骶前肿瘤的诊疗策略[J]. 临床外科杂志, 2023, 31(6): 509-513.
[12] 赵飞龙 吴文雅 田君 徐晓忠 鲍乐峰. 经自然腔道取标本手术对比传统腹腔镜手术在结直肠癌中的优势性及安全性分析 [J]. 临床外科杂志, 2023, 31(6): 538-541.
[13] 柳万忠 龙煊 邓志刚. 结直肠癌组织转录因子E2F2、黏蛋白样受体2水平与病人临床病理特征的关系及对淋巴结转移的诊断价值[J]. 临床外科杂志, 2023, 31(6): 542-545.
[14] 慕喜喜 李静 张玄 高小鹏 刘保荣 钟岳. miR-3619-5p、LINC00857在原发性肝细胞癌血清中表达水平及其临床诊断价值分析[J]. 临床外科杂志, 2023, 31(6): 572-575.
[15] 王新昇 吴世乐 贺贝贝 彭喆 陈宝章. 监测血钙、血清及中央区引流液甲状旁腺激素对甲状腺切除术后评估甲状旁腺功能的临床意义[J]. 临床外科杂志, 2023, 31(5): 428-431.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 栾杰. 当前国内乳房再造的几个原则与技术问题[J]. 临床外科杂志, 2020, 28(12): 1101 -1102 .
[2] 何雨竹, 倪鑫, 张潍平. 儿童先天性肾盂输尿管连接部梗阻性肾积水手术治疗策略研究进展[J]. 临床外科杂志, 2021, 29(6): 501 -504 .
[3] 马先桃 李师亮 严丽 朱章强 冯异 程才. 杂交技术在StanfordA型主动脉夹层的应用现状[J]. 临床外科杂志, 2021, 29(12): 1101 -1103 .
[4] 闵心平 夏军 朱铁源 胡知朋 李博文 徐鹏 王志维. 急性重症肺栓塞外科治疗八例[J]. 临床外科杂志, 2021, 29(12): 1132 -1134 .
[5] 李疆 曹英豪 邓胜和 蔡开琳. 胃下部癌No.6组淋巴结分拣特点和转移危险因素分析[J]. 临床外科杂志, 2022, 30(9): 830 -834 .
[6] 解东阳 张兵强 李韶山. 基于SEER数据库的壶腹周围癌预后预测模型的构建[J]. 临床外科杂志, 2023, 31(7): 659 -665 .
[7] 梁宾勇 陈孝平. 免疫治疗时代肝癌外科治疗的机遇与挑战[J]. 临床外科杂志, 2023, 31(10): 901 -903 .
[8] 魏萌萌 吕志坤 李国珍 胡雪艳 许倩倩 郭静 耿彪. 血清血管生成素样蛋白8、血管细胞黏附分子-1水平联合检测对颅内动脉瘤栓塞术后脑血管痉挛的预测价值[J]. 临床外科杂志, 2023, 31(12): 1133 -1136 .
[9] 方滢 叶哲伟 陈孝平. 科学技术对现代外科学发展的影响[J]. 临床外科杂志, 2024, 32(1): 1 -5 .
[10] 瞿伟峰 史颖弘 樊嘉. 美国国立综合癌症网络临床实践指南:肝细胞癌(2023.V2)更新解读[J]. 临床外科杂志, 2024, 32(1): 6 -9 .